Where is Mitotech located?

Mitotech is headquartered in Luxembourg, Luxembourg.

Who is the current CEO of Mitotech?

Natalia Perekhvatova of Mitotech.

How many employees does Mitotech have?

As of Jul 31, 2026, the latest employee count at Mitotech is 6.

Where does Mitotech rank among its competitors?

Mitotech ranks 2453rd amongst 2671 active competitors, of which 902 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Mitotech?

Mitotech's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Mitotech - 2026 Company Profile, Team & Competitors

Mitotech is an unfunded company based in Luxembourg (Luxembourg), founded in 2010. It operates as an A mitochondria-targeted antioxidant for the treatment of dry eyes and uveitis.. Mitotech has not raised any funding yet. The company has 2671 active competitors, including 902 funded and 682 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Mitotech is a clinical-stage biotechnology company with a portfolio of novel drugs for the treatment of age-related disorders. Its drug portfolio consists of an ophthalmic drug (Visomitin) and a systemic drug (Plastomitin). Both of its drug have SkQ1 – a mitochondria-targeted antioxidant – as their active ingredient. It is investigating Visomitin in patient with dry eyes (Phase 3) and uveitis (Phase 2). Visomitin™ already reached marketing approval for dry eye syndrome in Russia

Key Metrics

Founded Year

2010

Location

Luxembourg, Luxembourg

Stage

Unfunded

Ranked

2453^rd among 2671 active competitors

Employee Count

6 as on Jul 31, 2026

Similar Companies

Viridian Therapeutics & 300 more

View Mitotech's full profile

Mitotech has not raised any funding rounds yet.

Mitotech's employee count trend

Mitotech has 6 employees as of Jul 26. Here is Mitotech's employee count trend over the years:

Uncover Mitotech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mitotech include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Mitotech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
2453rd	Mitotech 2010, Luxembourg (Luxembourg), Unfunded	A mitochondria-targeted antioxidant for the treatment of dry eyes and uveitis.	-	-	21/100